Jacob Van Naarden
CIK 1661254 · EVP,Pres LLY Oncology&HdCorpBD · last filed 2026-02-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$36.17M
Companies
2
Total Filings
35
Lifetime Open-Market Net
-$11.12M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LLY | EVP,Pres LLY Oncology&HdCorpBD | 31,928 | $1133.00 | $36.17M | $647.4K | 12 | 2026-02-11 |
| Loxo Oncology, Inc. (LOXO) Delisted | Chief Operating Officer | 0 | — | — | -$11.77M | 23 | 2019-02-15 |
Recent Filings · Page 4 of 4
35 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-11-01 | Loxo Oncology, Inc. (LOXO) Delisted | Mixed | — | -$256.5K | EDGAR |
| 2017-09-20 | Loxo Oncology, Inc. (LOXO) Delisted | Mixed | — | -$263.0K | EDGAR |
| 2017-08-16 | Loxo Oncology, Inc. (LOXO) Delisted | Mixed | — | -$215.5K | EDGAR |
| 2017-03-17 | Loxo Oncology, Inc. (LOXO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-08 | Loxo Oncology, Inc. (LOXO) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 31–35 of 35
Prev
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.